News
Public · Published
BTIG reiterates Buy rating on Faeth Therapeutics, $55 price target
BTIG reiterated a Buy rating on Faeth Therapeutics stock with a $55.00 price target. That target implies upside of 226.8% from the October 26 close of $16.83.
Published:
Updated:
What happened
BTIG reiterated a Buy rating on Faeth Therapeutics stock with a $55.00 price target. That target implies upside of 226.8% from the October 26 close of $16.83.
Confirmed
Global impact / market context
A repeated Buy rating signals that BTIG still expects Faeth's cancer drug program to succeed commercially. For investors, the large implied gain suggests the analyst sees the current share price as far below what the company could be worth if its treatments progress.
Analyst inference
The note frames Faeth's PIKTOR program as promising in endometrial and breast cancer, where patients lack good options. Its oral pill form, which means patients swallow it rather than receive infusions, and better tolerability could support uptake and patient adherence if approved.
Analyst inference
What to watch
- BTIG's $55.00 target rests on PIKTOR showing strong efficacy and safety in clinical testing for endometrial and breast cancer, so trial results will test that view. Confirmed
- Watch whether Faeth reports further PIKTOR clinical data on how well patients tolerate the oral treatment, since BTIG cited tolerability as a competitive advantage. Proposed
- Track whether other analysts change their ratings or targets, because a single reiterated Buy with a 226.8% implied gain may not reflect wider investor positioning. Analyst inference
Evidence
- Original source link unavailable